Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers

NCT05259696 is registered in ClinicalTrials.gov with Palleon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05259696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05259696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
Lead sponsor
Palleon Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 11, 2022
Completion date
October 24, 2024
Enrollment
69 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, cancer, colon cancer, colorectal cancer, crc, egj, esophagogastric junction cancer, gastric cancer, head and neck cancer, melanoma, non small cell lung cancer, nsclc, oncology, ovarian cancer, pancreatic cancer, urothelial cancer